Australian Technical Advisory Group on Immunisation (ATAGI)

Role

ATAGI's role is to:

advise the Minister for Health and Aged Care on the medical administration of vaccines available in Australia, including those available through the National Immunisation Program (NIP)
provide advice to research organisations on current immunisation research and areas that need more research
provide industry sponsors with pre-submission advice for potential submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) on vaccine effectiveness and use in Australia. ATAGI advice must be sought prior to a sponsor making a submission to the PBAC (see parallel processing requirements for PBAC vaccine submissions and pre-submission advice for industry sponsors wishing to make a PBAC submission)
consult with relevant organisations to produce the Australian Immunisation Handbook
consult with relevant organisations in implementing immunisation policies, procedures and vaccine safety.

For more detail, take a look at:

Members

Consideration of recommendations relating to COVID-19 vaccines is now managed through regular ATAGI meetings.

Voting members

Name	Area of expertise	Position
Prof Nigel Crawford	Chair, Vaccine Safety, Special Risk Groups	Director, Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC), Murdoch Children’s Research Institute Medical Head, Immunisation Services Royal Children’s Hospital, Melbourne Senior Fellow, Department of Paediatrics, University of Melbourne
Prof Michelle Giles	Deputy Chair, Infectious Disease Physician, Maternal Immunisation	Director, Infections in Pregnancy service, Monash Infectious Diseases Infectious Diseases Physician (Alfred Health, Monash Health, Royal Women’s Hospital, Sunshine Hospital) Professor, Department of Obstetrics and Gynaecology, Monash University Department of Infectious Diseases, the Peter Doherty Institute for Infection and Immunity, University of Melbourne
Prof Allen Cheng	Epidemiology, Public Health	Infectious Disease Physician and Director, Infection Prevention Healthcare Epidemiology Unit, Alfred Health
Ms Karen Bellamy	Immunisation Nurse Practitioner	Monash Health, South East Public Health Unit (SEPHU)
Prof Katie Flanagan	Infectious Diseases	Director of Infectious Diseases, Launceston General Hospital Adjunct Professor, School of Medicine, University of Tasmania Adjunct Professor, School of Health and Biomedical Science, RMIT
Dr Katherine Gibney	Infectious Diseases and Public Health Physician, Epidemiology	Infectious Diseases Physician, Victorian Infectious Diseases Service, The Royal Melbourne Hospital Senior Research Fellow, The Peter Doherty Institute for Infection and Immunity
A/Prof Penelope Burns	General Practitioner	Clinical Associate Professor, Australian National University Conjoint Senior Lecturer Western Sydney University
Dr Nicholas Silberstein	General Practitioner	General Practitioner, Victoria
Prof James Wood	Infectious Diseases Epidemiology, Population Health	Associate Professor, School of Public Health and Community Medicine, UNSW Sydney
Ms Diane Walsh	Consumer Health Issues	Consumers Health Forum
Ms Kristy Cooper	Senior Nurse Practitioner	Aboriginal, Torres Strait Islander Representative Primary Health Care / Family Nurse Practitioner Authorised Tasmanian Immunisation Provider Tasmanian Aboriginal Health Service
Assoc. Prof. Benjamin Teh	Infectious Disease Physician	Infectious Diseases Physician, Peter MacCallum Cancer Centre Honorary Principal Research Fellow, University of Melbourne
Dr Julia Marshall	General Practitioner	General Practitioner, Victoria Medical Advisor, North Eastern Public Health Unit, Austin Health Clinician Scientist (Vaccinology), The Peter Doherty Institute for Infection and Immunity
Prof Margaret Danchin	Consultant Paediatrician	Consultant Paediatrician, Department of General Medicine, Royal Children’s Hospital Group Leader, Vaccine Uptake, Murdoch Children’s Research Institute Professor, Department of Paediatrics, University of Melbourne
Dr Rosalind Webby	Medical Advisor	Medical Advisor, Immunisation and Rheumatic Heart Disease, Centre for Disease Control, Northern Territory Department of Health

Ex-officio members

Name	Area of expertise	Position
Dr Marcelle Noja	Representative from the Department of Health and Aged Care	Assistant Secretary, Immunisation Branch, Department of Health, and Aged Care
Dr Yashwant Sinha	Representative from the Therapeutic Goods Administration	Office of Medicines Authorisation Market Authorisation Group, Therapeutic Goods Administration
Prof Kristine Macartney	National Centre for Immunisation Research and Surveillance (NCIRS)	Director, National Centre for Immunisation Research and Surveillance Paediatrician and Infectious Diseases Specialist
Ms Catherine Radkowski	Jurisdiction Immunisation Committee (JIC)	Senior Technical Specialist, Immunisation Unit, Health Protection Branch, Department of Health, Victoria
Dr Heidi Carroll	Representative from Communicable Diseases Network Australia (CDNA)	Deputy Executive Director – Communicable Diseases Branch
Prof. Andrew Wilson	Pharmaceutical Benefits Advisory Committee (PBAC)	Chair, Pharmaceutical Benefits Advisory Committee
Ms Jo Watson	Pharmaceutical Benefits Advisory Committee (PBAC)	Deputy Chair, Pharmaceutical Benefits Advisory Committee

Membership guidelines

Statements

COVID-19 vaccination statements

20 November 2023 – ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines
1 September 2023 – ATAGI Update on the COVID-19 Vaccination Program
30 May 2023 – ATAGI advice on the preferential use of bivalent COVID-19 vaccines for primary vaccination of people aged 12 years or older
28 February 2023 – ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
8 February 2023 – ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
8 February 2023 – update to the ATAGI COVID-19 vaccine booster advice
15 November 2022 – ATAGI recommendations on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years
15 November 2022 – ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
24 October 2022 – ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years
23 September 2022 – updated guidance on myocarditis and pericarditis after COVID-19 vaccines
12 September 2022 – statement on use of the Moderna bivalent Original/Omicron vaccine
25 August 2022 – Novavax vaccine for adolescents aged 12-17 years
3 August 2022 – ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years
7 July 2022 – updated recommendations for a winter dose of the COVID-19 vaccine
9 June 2022 – on the use of a first booster dose in adolescents aged 12-15 years
25 May 2022 – expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
8 April 2022 – on use of booster doses in adolescents aged 12-15 years
6 April 2022 – advice on the use of sedation for COVID-19 vaccination
25 March 2022 – recommendations on a winter booster dose of COVID-19 vaccine
2 March 2022 – updated statement on the use of a booster dose of COVID-19 vaccine
23 February 2022 – recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years
3 February 2022 – recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years
24 January 2022 – statement on the use of the Novavax vaccine for those 18 years and older
24 January 2022 – guidance on temporary medical exemptions – reduced to 4 months after testing positive for COVID-19
17 January 2022 – recommendations for a third primary dose for people aged 5 years and older who are severely immunocompromised
24 December 2021 – statement on Omicron variant and the timing of COVID-19 booster vaccination
17 December 2021 – statement on Omicron variant
12 December 2021 – Omicron variant and timing of COVID-19 booster vaccination
12 December 2021 – recommendations on the use of Spikevax (Moderna) as a COVID-19 booster vaccine
10 December 2021 – response to ATAGI advice about vaccinating 5 to 11-year-olds against COVID-19
7 December 2021 – advice on the administration of seasonal influenza vaccines in 2021 (December 2021)
3 December 2021 – on SARS-CoV-2 Omicron variant and COVID-19 booster doses
28 October 2021 – recommendations on the use of a booster dose of COVID-19 vaccine
8 October 2021 – on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised
23 September 2021 – on the need for additional doses of COVID-19 vaccines
27 August 2021 – on the use of COVID-19 vaccines in all young adolescents in Australia
9 August 2021 – on considerations for establishing drive-through COVID-19 vaccination clinic sites
2 August 2021 – regarding COVID-19 vaccines in the setting of transmission of the Delta variant of concern
24 July 2021 – response to NSW COVID-19 outbreak 24th July 2021
13 July 2021 – on the use of COVID-19 vaccines in an outbreak setting
17 June 2021 – on revised recommendations on the use of COVID-19 Vaccine AstraZeneca
9 June 2021 – joint statement between RANZCOG and ATAGI about COVID-19 vaccination for pregnant women
23 May 2021 – joint statement on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca
23 April 2021 – on use of COVID-19 vaccines following review of vaccine safety data and benefits
8 April 2021 – on AstraZeneca vaccine in response to new vaccine safety concerns
2 April 2021 – on COVID-19 vaccination and a reported case of thrombosis
2 April 2021 – for consumers on a specific clotting condition being reported after COVID-19 vaccination
25 March 2021 – for health care providers on suitability of COVID-19 vaccination in people with history of clotting conditions
19 March 2021 – statement and clinical guidance on AstraZeneca COVID-19 vaccine following European Medicines Agency (EMA) safety review
16 March 2021 – in response to European decisions about the AstraZeneca vaccine

COVID-19 updates

15 November 2022 – update following COVID-19 meeting – 11 November
14 September 2022 – update following weekly COVID-19 meeting – 7 September
2 September 2022 – update following weekly COVID-19 meeting – 31 August 2022
26 August 2022 – update following weekly COVID-19 meeting – 24 August 2022
3 August 2022 – recommendations COVID-19 vaccine for children aged 6 months to under 5 years
27 July 2022 – ongoing review of COVID-19 vaccine for children aged 6 months to under 5 years and ongoing safety review of COVID-19 vaccines
20 July 2022 – update on WHO TAG-CO-VAC, impact of COVID-19 vaccination in children
13 July 2022 – Impact of COVID-19 vaccination in children, 4^th dose reinfection interval and use in pregnancy
6 July 2022 – Update to the recommendations for a 4^th (winter dose) of a COVID-19 vaccine
29 June 2022 – Update to the recommendations on Novavax COVID-19 boosters, review of additional booster (winter) doses, review of data on impact of COVID-19 on children
1 June 2022 – Update following weekly COVID-19 meeting
25 May 2022 – Expanded winter boosters and ongoing review of boosters for 12-15 year olds
23 May 2022 – Ongoing review of adverse events and safety information
11 May 2022 – Omicron vaccine effectiveness and ongoing review of COVID-19 booster
4 May 2022 – Ongoing review of COVID-19 booster and safety information
27 April 2022 – Updates to mRNA COVID-19 vaccine dose intervals, rates of myocarditis and pericarditis and timing of vaccination post infection
20 April 2022 – Recommendations on boosters for 12-15 year old adolescents
30 March 2022 – Resources on additional winter booster doses, use of sedation for COVID-19 vaccination
23 March 2022 – Recommendations on a winter booster dose of COVID-19 vaccine
16 March 2022 – Consideration of second COVID-19 booster doses
9 March 2022 – Evidence relating to second COVID-19 booster doses
2 March 2022 – Advice on booster vaccines
23 February 2022 – 6-11 Moderna, clinical guidance, medical exemptions for COVID-19 vaccines
16 February 2022 – RATs as proof of infection, 6-11 Moderna, Novavax booster
9 February 2022 – Defining ‘up-to-date’ status, duration of observation after COVID-19 vaccination
2 February 2022 – Boosters for adolescents aged 16-17 years
27 January 2022 – Vaccination post-infection
19 January 2022 – Vaccination post-infection, Novavax registration, dose interval in children aged 5 to 11 years
12 January 2022 – Dose intervals for vaccination of 5-11 year old children, safety update
22 December 2021
15 December 2021
8 December 2021
1 December 2021
24 November 2021
17 November 2021
10 November 2021
3 November 2021
27 October 2021
20 October 2021
13 October 2021
6 October 2021
29 September 2021
22 September 2021
15 September 2021
8 September 2021
1 September 2021
25 August 2021
19 August 2021
11 August 2021
4 August 2021
28 July 2021
21 July 2021
14 July 2021
7 July 2021
30 June 2021
23 June 2021
9 June 2021
2 June 2021
26 May 2021
19 May 2021
12 May 2021
4 May 2021
28 April 2021

Meetings

Australian Technical Advisory Group on Immunisation (ATAGI) – Meetings

A collection of ATAGI meeting bulletins.

ATAGI advice

COVID-19 vaccination – Provider resources

Read and download clinical guidance and other resources for COVID-19 vaccines provided by the Australian Technical Advisory Group on Immunisation (ATAGI).

COVID-19 vaccination – Patient resources

This collection contains resources for patients receiving a COVID-19 vaccination.

Contact

If your query is regarding COVID-19 vaccine eligibility, supply and demand or any other COVID 19 related query, further information can be found on the COVID-19 vaccines webpage.

Media enquiries should be directed to news@health.gov.au. Individual ATAGI members are not authorised to speak on behalf of ATAGI.

For all other enquiries please email enquiries@health.gov.au.

Date last updated:

20 November 2023

Tags:

Immunisation